Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798632 | 0.82 | CYP1A2 (0.70) | PTPN22THRBHSD17B10CYP1A2HPGD | |
| SCHEMBL4847752 | 0.78 | HSD17B10 (0.68) | THRBHSD17B10CYP1A2HPGDALDH1A1 | |
| SCHEMBL29613397 | 0.78 | HSD17B10 (0.68) | THRBHSD17B10CYP1A2HPGDALDH1A1 | |
| SCHEMBL31229442 | 0.78 | CYP1A2 (0.47) | PTPN22THRBHSD17B10CYP1A2HPGD | |
| SCHEMBL9157679 | 0.78 | HSD17B10 (0.68) | THRBHSD17B10CYP1A2HPGDALDH1A1 | |
| SCHEMBL4852312 | 0.78 | HSD17B10 (0.68) | THRBHSD17B10CYP1A2HPGDALDH1A1 | |
| SCHEMBL11076300 | 0.78 | IDO1 (0.61) | PTPN22THRBHSD17B10CYP1A2HPGD | |
| SCHEMBL16554732 | 0.78 | TRPM4 (0.52) | PTPN22THRBHSD17B10CYP1A2HPGD | |
| SCHEMBL864719 | 0.77 | CYP1A2 (0.55) | PTPN22THRBHSD17B10CYP1A2HPGD | |
| SCHEMBL145008 | 0.76 | PIM1 (0.61) | PTPN22THRBHSD17B10CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3813851-A1 | IMPROVEMENT OF BLOOD MICROPERFUSION TO SKIN BY SHILAJIT | Natreon, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| EP-3200761-A1 | PROMOTING MUSCLE BUILDING AND REPAIR AND TREATING DISORDERS RELATED TO COLLAGEN AND PERTINENT PROTEINS BY USING SHILAJIT | Natreon Inc. (US) | 2017-08-09 | — | — | EP | claimed |
| WO-2016054433-A1 | PROMOTING MUSCLE BUILDING AND REPAIR AND TREATING DISORDERS RELATED TO COLLAGEN AND PERTINENT PROTEINS BY USING SHILAJIT | NATREON, INC. (US) | 2016-04-07 | — | — | WO | claimed |
| EP-3876968-A1 | ANTI-DIABETIC ACTIVITY OF NEEM EXTRACT AND SYNERGISTIC COMBINATIONS OF UROLITHINS A AND B | Natreon, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3813851-A1 | IMPROVEMENT OF BLOOD MICROPERFUSION TO SKIN BY SHILAJIT | Natreon, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3755320-A1 | SYNERGISTIC COMBINATIONS OF UROLITHINS A AND B FOR IMPROVING COGNITIVE CAPACITY OR COGNITIVE FUNCTION | Natreon Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10857126-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2020-12-08 | — | — | US | disclosed |
| WO-2019160588-A1 | SYNERGISTIC COMBINATIONS OF UROLITHINS A AND B FOR IMPROVING COGNITIVE CAPACITY OR COGNITIVE FUNCTION | NATREON, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| EP-3200761-A1 | PROMOTING MUSCLE BUILDING AND REPAIR AND TREATING DISORDERS RELATED TO COLLAGEN AND PERTINENT PROTEINS BY USING SHILAJIT | Natreon Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170143666-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20160220609-A1 | REGULATION OF STEROIDOGENIC ACTIVITY BY USING PURIFIED SHILAJIT | NATREON, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3033148-A1 | REGULATION OF BODY WEIGHT GAIN BY USING DIBENZO-ALPHA-PYRONES | Natreon, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2016054433-A1 | PROMOTING MUSCLE BUILDING AND REPAIR AND TREATING DISORDERS RELATED TO COLLAGEN AND PERTINENT PROTEINS BY USING SHILAJIT | NATREON, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015035358-A1 | REGULATION OF STEROIDOGENIC ACTIVITY BY USING PURIFIED SHILAJIT | NATREON, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035391-A1 | REGULATION OF BODY WEIGHT GAIN BY USING DIBENZO-ALPHA-PYRONES | NATREON, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2654461-A2 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODENEGENERATIVE DISEASES AND COGNITIVE DISORDERS | Amazentis SA (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088519-A2 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODENEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143666-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | NLN, TUFM, TFAM | PTPN22 4594/4885THRB 3120/4885HSD17B10 493/4885 |
| US-10857126-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | NLN, TUFM, TFAM | PTPN22 4670/4885THRB 3429/4885HSD17B10 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.